Q-omics provides the consensus-scored PRR12 profile across patient tissues and cancer cell-line models. PRR12 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PRR12 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, PRR12 protein abundance shows 28,294 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, and LSCC as cancer lineages where PRR12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRR12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRR12 survival associations across molecular data types. PRR12 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRR12 RNA expression–survival associations across cancer types. High PRR12 expression shows unfavorable associations in MESO, ACC and LUSC, but favorable associations in HNSC, SCLC and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for PRR12 RNA expression.
This table summarizes PRR12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PRR12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRR12 shows higher tumor expression in HNSC, LIHC, COAD, STAD, BRCA and CHOL. The HNSC box plot shows higher PRR12 RNA expression in tumor versus normal tissue (log2 FC = +0.901, t-test p < 0.001).
This table shows molecular features associated with PRR12 in patient tissues and cancer cell lines. In patient samples, PRR12 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PRR12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
